{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T21:48:58Z","timestamp":1780091338436,"version":"3.54.0"},"reference-count":27,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2013,7,1]],"date-time":"2013-07-01T00:00:00Z","timestamp":1372636800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,7,1]],"date-time":"2013-07-01T00:00:00Z","timestamp":1372636800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinicaloncologyonline.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Oncology"],"published-print":{"date-parts":[[2013,7]]},"DOI":"10.1016\/j.clon.2013.03.003","type":"journal-article","created":{"date-parts":[[2013,4,10]],"date-time":"2013-04-10T01:30:38Z","timestamp":1365557438000},"page":"435-444","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":33,"title":["Incidence of Skeletal-related Events Over Time from Solid Tumour Bone Metastases Reported in Randomised Trials Using Bone-modifying Agents"],"prefix":"10.1016","volume":"25","author":[{"given":"M.","family":"Poon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Lam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"U.","family":"Emmenegger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Bedard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Lao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Chow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Chow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.clon.2013.03.003_bib1","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1002\/(SICI)1097-0142(20000301)88:5<1082::AID-CNCR20>3.0.CO;2-Z","article-title":"Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastases: long term follow-up of two randomized, placebo-controlled trials","volume":"88","author":"Lipton","year":"2000","journal-title":"Cancer"},{"issue":"3","key":"10.1016\/j.clon.2013.03.003_bib2","first-page":"163","article-title":"Effect of bisphosphonates on pain and quality of life in patients with bone metastases","volume":"6","author":"Costa","year":"2009","journal-title":"Nat Clin Pract Oncol"},{"issue":"3","key":"10.1016\/j.clon.2013.03.003_bib3","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1200\/JCO.1999.17.3.846","article-title":"Pamidronate reduces skeletal morbidity in women with advanced breast cancer and lytic bone lesions: a randomized, placebo-controlled trial. Protocol 18 Aredia Breast Cancer Study Group","volume":"17","author":"Theriault","year":"1999","journal-title":"J\u00a0Clin Oncol"},{"issue":"9","key":"10.1016\/j.clon.2013.03.003_bib4","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1200\/JCO.2010.31.3304","article-title":"Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma","volume":"29","author":"Henry","year":"2011","journal-title":"J\u00a0Clin Oncol"},{"issue":"6","key":"10.1016\/j.clon.2013.03.003_bib5","doi-asserted-by":"crossref","first-page":"390","DOI":"10.3816\/CGC.2007.n.022","article-title":"Continuing benefit of zoledronic acid in preventing skeletal complications in patients with bone metastases","volume":"5","author":"Saad","year":"2007","journal-title":"Clin Genitourin Cancer"},{"issue":"1","key":"10.1016\/j.clon.2013.03.003_bib6","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1002\/1097-0142(19860701)58:1<178::AID-CNCR2820580130>3.0.CO;2-T","article-title":"Breast cancer with skeletal metastases at initial diagnosis. Distinctive clinical characteristics and favorable prognosis","volume":"58","author":"Sherry","year":"1986","journal-title":"Cancer"},{"issue":"4","key":"10.1016\/j.clon.2013.03.003_bib7","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1016\/S0959-8049(99)00331-7","article-title":"Risk of complications from bone metastases in breast cancer. Implications for management","volume":"36","author":"Plunkett","year":"2000","journal-title":"Eur J Cancer"},{"issue":"19","key":"10.1016\/j.clon.2013.03.003_bib8","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1093\/jnci\/94.19.1458","article-title":"A\u00a0randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma","volume":"94","author":"Saad","year":"2002","journal-title":"J\u00a0Natl Cancer Inst"},{"issue":"12","key":"10.1016\/j.clon.2013.03.003_bib9","first-page":"3307","article-title":"An international prospective study establishing minimal clinically important differences in the EORTC QLQ-BM22 and QLQ-C30 in cancer patients with bone metastases","volume":"20","author":"Zeng","year":"2012","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.clon.2013.03.003_bib10","first-page":"27","article-title":"Bisphosphonates in oncology: evidence for the prevention of skeletal events in patients with bone metastases","volume":"3","author":"Polascik","year":"2009","journal-title":"Drug Des Devel Ther"},{"issue":"5-6","key":"10.1016\/j.clon.2013.03.003_bib11","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1159\/000082923","article-title":"The cost of treatment of skeletal-related events in patients with bone metastases from lung cancer","volume":"67","author":"Delea","year":"2004","journal-title":"Oncology"},{"issue":"35","key":"10.1016\/j.clon.2013.03.003_bib12","doi-asserted-by":"crossref","first-page":"5132","DOI":"10.1200\/JCO.2010.29.7101","article-title":"Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study","volume":"28","author":"Stopeck","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"issue":"17","key":"10.1016\/j.clon.2013.03.003_bib13","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1093\/jnci\/djg038","article-title":"A\u00a0double-blind, placebo-controlled, randomized trial of oral sodium clodronate for metastatic prostate cancer (MRC PR05 Trial)","volume":"95","author":"Dearnaley","year":"2003","journal-title":"J\u00a0Natl Cancer Inst"},{"issue":"24","key":"10.1016\/j.clon.2013.03.003_bib14","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.1056\/NEJM199612123352401","article-title":"Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. Protocol 19 Aredia Breast Cancer Study Group","volume":"335","author":"Hortobagyi","year":"1996","journal-title":"N\u00a0Engl J Med"},{"issue":"23","key":"10.1016\/j.clon.2013.03.003_bib15","doi-asserted-by":"crossref","first-page":"4277","DOI":"10.1200\/JCO.2003.05.147","article-title":"Combined analysis of two multicenter, randomized, placebo-controlled studies of pamidronate disodium for the palliation of bone pain in men with metastatic prostate cancer","volume":"21","author":"Small","year":"2003","journal-title":"J\u00a0Clin Oncol"},{"issue":"15","key":"10.1016\/j.clon.2013.03.003_bib16","doi-asserted-by":"crossref","first-page":"3314","DOI":"10.1200\/JCO.2005.05.116","article-title":"Zoledronic acid significantly reduces skeletal complications compared with placebo in Japanese women with bone metastases from breast cancer: a\u00a0randomized, placebo-controlled trial","volume":"23","author":"Kohno","year":"2005","journal-title":"J\u00a0Clin Oncol"},{"issue":"5","key":"10.1016\/j.clon.2013.03.003_bib17","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1002\/cncr.11571","article-title":"Zoledronic acid delays the onset of skeletal-related events and progression of skeletal disease in patients with advanced renal cell carcinoma","volume":"98","author":"Lipton","year":"2003","journal-title":"Cancer"},{"issue":"12","key":"10.1016\/j.clon.2013.03.003_bib18","doi-asserted-by":"crossref","first-page":"2613","DOI":"10.1002\/cncr.20308","article-title":"Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and other solid tumors: a randomized, phase III, double-blind, placebo-controlled trial","volume":"100","author":"Rosen","year":"2004","journal-title":"Cancer"},{"issue":"9768","key":"10.1016\/j.clon.2013.03.003_bib19","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1016\/S0140-6736(10)62344-6","article-title":"Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study","volume":"377","author":"Fizazi","year":"2011","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.clon.2013.03.003_bib20","first-page":"302","article-title":"Mortality and complications following stabilization of femoral metastatic lesions: a population-based study of regional variation and outcome","volume":"52","author":"Ristevski","year":"2009","journal-title":"Can J Surg"},{"issue":"8 Suppl.","key":"10.1016\/j.clon.2013.03.003_bib21","doi-asserted-by":"crossref","first-page":"1614","DOI":"10.1002\/(SICI)1097-0142(19971015)80:8+<1614::AID-CNCR12>3.0.CO;2-2","article-title":"Orthopedic surgical management of skeletal complications of malignancy","volume":"80","author":"Harrington","year":"1997","journal-title":"Cancer"},{"issue":"5","key":"10.1016\/j.clon.2013.03.003_bib22","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1002\/cncr.23259","article-title":"Effective inhibition of aromatase inhibitor-associated bone loss by zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole","volume":"112","author":"Bundred","year":"2008","journal-title":"Cancer"},{"issue":"5","key":"10.1016\/j.clon.2013.03.003_bib23","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1586\/era.10.47","article-title":"Management of metastatic spinal cord compression","volume":"10","author":"Shiue","year":"2010","journal-title":"Expert Rev Anticancer Ther"},{"issue":"3","key":"10.1016\/j.clon.2013.03.003_bib24","first-page":"549","article-title":"Comparing baseline symptom severity and demographics over two time periods in an outpatient palliative radiotherapy clinic","volume":"20","author":"Khan","year":"2012","journal-title":"Support Care Cancer"},{"issue":"2","key":"10.1016\/j.clon.2013.03.003_bib25","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/S0885-3924(01)00406-7","article-title":"Do hospital-based palliative teams improve care for patients or families at the end of life?","volume":"23","author":"Higginson","year":"2002","journal-title":"J\u00a0Pain Symptom Manage"},{"issue":"2","key":"10.1016\/j.clon.2013.03.003_bib26","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1053\/j.seminoncol.2004.11.015","article-title":"Integration of palliative medicine into comprehensive cancer care","volume":"32","author":"Lagman","year":"2005","journal-title":"Semin Oncol"},{"issue":"7","key":"10.1016\/j.clon.2013.03.003_bib27","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1634\/theoncologist.11-7-841","article-title":"Efficacy and safety of zoledronic acid in patients with breast cancer metastatic to bone: a multicenter clinical trial","volume":"11","author":"Carteni","year":"2006","journal-title":"Oncologist"}],"container-title":["Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0936655513001301?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0936655513001301?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T15:38:59Z","timestamp":1760542739000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0936655513001301"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,7]]},"references-count":27,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2013,7]]}},"alternative-id":["S0936655513001301"],"URL":"https:\/\/doi.org\/10.1016\/j.clon.2013.03.003","relation":{},"ISSN":["0936-6555"],"issn-type":[{"value":"0936-6555","type":"print"}],"subject":[],"published":{"date-parts":[[2013,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Incidence of Skeletal-related Events Over Time from Solid Tumour Bone Metastases Reported in Randomised Trials Using Bone-modifying Agents","name":"articletitle","label":"Article Title"},{"value":"Clinical Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clon.2013.03.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 The Royal College of Radiologists. Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}